| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
XORTX Therapeutics Inc. Common Stock (OTCQB: XRTX)
XRTX Technical Analysis
2.5
| As on 2nd Jan 2025 XRTX STOCK Price closed @ 1.12 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.93 & Strong Buy for SHORT-TERM with Stoploss of 0.65 we also expect STOCK to react on Following IMPORTANT LEVELS. |
XRTXSTOCK Price
| Open | 1.12 | Change | Price | % |
| High | 1.18 | 1 Day | -0.02 | -1.75 |
| Low | 1.09 | 1 Week | -0.07 | -5.88 |
| Close | 1.12 | 1 Month | -0.31 | -21.68 |
| Volume | 6661 | 1 Year | 0.48 | 75.00 |
| 52 Week High 6.25 | 52 Week Low 0.26 | ||||
OTCQB USA Most Active Stocks
| BGLC | 0.55 | 96.43% |
| ABQQ | 0.00 | % |
| FNMAS | 10.12 | 2.33% |
| FMCKJ | 9.73 | 0.83% |
| EFSH | 0.29 | 16.00% |
| BMIX | 0.01 | % |
| FNMA | 3.44 | 4.88% |
| BTCWF | 0.10 | 150.00% |
| ALPP | 3.56 | 0.00% |
| ALPP | 3.56 | 0.00% |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| XRTX Daily Charts |
XRTX Intraday Charts |
Whats New @ Bazaartrend |
XRTX Free Analysis |
|
|
XRTX Important Levels Intraday
| RESISTANCE | 1.29 |
| RESISTANCE | 1.24 |
| RESISTANCE | 1.20 |
| RESISTANCE | 1.17 |
| SUPPORT | 1.07 |
| SUPPORT | 1.04 |
| SUPPORT | 1.00 |
| SUPPORT | 0.95 |
XRTX Forecast January 2025
| 4th UP Forecast | 1.83 |
| 3rd UP Forecast | 1.6 |
| 2nd UP Forecast | 1.46 |
| 1st UP Forecast | 1.32 |
| 1st DOWN Forecast | 0.92 |
| 2nd DOWN Forecast | 0.78 |
| 3rd DOWN Forecast | 0.64 |
| 4th DOWN Forecast | 0.41 |
XRTX Weekly Forecast
| 4th UP Forecast | 1.47 |
| 3rd UP Forecast | 1.36 |
| 2nd UP Forecast | 1.29 |
| 1st UP Forecast | 1.22 |
| 1st DOWN Forecast | 1.02 |
| 2nd DOWN Forecast | 0.95 |
| 3rd DOWN Forecast | 0.88 |
| 4th DOWN Forecast | 0.77 |
XRTX Forecast2025
| 4th UP Forecast | 14.13 |
| 3rd UP Forecast | 9.96 |
| 2nd UP Forecast | 7.38 |
| 1st UP Forecast | 4.8 |
| 1st DOWN Forecast | -2.56 |
| 2nd DOWN Forecast | -5.14 |
| 3rd DOWN Forecast | -7.72 |
| 4th DOWN Forecast | -11.89 |
XORTX Therapeutics Inc. Common Stock ( OTCQB USA Symbol : XRTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
XRTX Business Profile
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service